We are a publicly traded biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. Our proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships City of Hope: running and funding the investigator-initiated Phase 1 trial. Northwestern University: worldwide exclusive license for NSC-CRAd-S-pk7 materials (neural-stem-cell-delivered oncolytic adenovirus); best-efforts commitment to fund up to $10M toward a phase 2 trial
Indications
Malignant glioma / high-grade glioma(Phase 1)
Status note Oncolytic virus embedded in stem cells. Phase 1 trial being run and funded by City of Hope as an investigator-initiated trial; Northwestern also running a Phase 1 of repeated neural-stem-cell virotherapy + N-acetylcysteine + standard chemoRT for newly diagnosed high-grade glioma under a December 2024 investigator-initiated trial agreement.
SuperNova
Phase 1 · ActiveModality: oncolytic virus
Aliases CLD-201
Indications
Soft tissue sarcoma(Phase 1)
Status note Oncolytic virus embedded in stem cells. Open IND for a Phase 1 trial; FDA Fast Track Designation granted July 2025 for soft tissue sarcoma.
CLD-401
Preclinical · ActiveModality: oncolytic virus
Indications
Metastatic solid tumors(Preclinical)
Status note First lead from the RedTail platform: enveloped oncolytic virus. Preclinical.
CLD-501
Preclinical · ActiveModality: oncolytic virus
Target TROP2
Indications
Cancer(Preclinical)
Status note RedTail-platform preclinical lead.
CLD-502
Preclinical · ActiveModality: oncolytic virus
Target EpCAM
Indications
Cancer(Preclinical)
Status note RedTail-platform preclinical lead.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.